These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23347632)

  • 21. Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems.
    Talisuna AO; Karema C; Ogutu B; Juma E; Logedi J; Nyandigisi A; Mulenga M; Mbacham WF; Roper C; Guerin PJ; D'Alessandro U; Snow RW
    Lancet Infect Dis; 2012 Nov; 12(11):888-96. PubMed ID: 23099083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Editorial commentary: single-dose primaquine as gametocytocidal treatment in patients with uncomplicated falciparum malaria.
    Dondorp AM
    Clin Infect Dis; 2013 Mar; 56(5):694-6. PubMed ID: 23175557
    [No Abstract]   [Full Text] [Related]  

  • 23. Tracking artemisinin resistance in Plasmodium falciparum.
    Sibley CH
    Lancet Infect Dis; 2013 Dec; 13(12):999-1000. PubMed ID: 24035557
    [No Abstract]   [Full Text] [Related]  

  • 24. Parenteral Artesunate for Severe Imported Plasmodium falciparum Malaria in Children.
    Levy M; Pham LL; Faye A; de Suremain N; Rambaud J; Angoulvant A; Miatello J; Dauger S; Naudin J
    Pediatr Infect Dis J; 2016 Sep; 35(9):1053-4. PubMed ID: 27518753
    [No Abstract]   [Full Text] [Related]  

  • 25. Artemisinin resistance in Plasmodium falciparum.
    Amaratunga C; Witkowski B; Khim N; Menard D; Fairhurst RM
    Lancet Infect Dis; 2014 Jun; 14(6):449-50. PubMed ID: 24849722
    [No Abstract]   [Full Text] [Related]  

  • 26. Altered drug susceptibility during host adaptation of a Plasmodium falciparum strain in a non-human primate model.
    Obaldía N; Dow GS; Gerena L; Kyle D; Otero W; Mantel PY; Baro N; Daniels R; Mukherjee A; Childs LM; Buckee C; Duraisingh MT; Volkman SK; Wirth DF; Marti M
    Sci Rep; 2016 Feb; 6():21216. PubMed ID: 26880111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microbiology. Eliminating malaria.
    Fidock DA
    Science; 2013 Jun; 340(6140):1531-3. PubMed ID: 23812705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia.
    Osorio L; Gonzalez I; Olliaro P; Taylor WR
    Malar J; 2007 Feb; 6():25. PubMed ID: 17328806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why the world needs another malaria initiative.
    Lancet; 2004 Jul 31-Aug 6; 364(9432):389-90. PubMed ID: 15288715
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic efficacy of artemisinin combination therapies and prevalence of S769N mutation in PfATPase6 gene of Plasmodium falciparum in Kolkata, India.
    Saha P; Naskar A; Ganguly S; Das S; Guha SK; Biswas A; Bera DK; Kundu PK; Das M; Mullick S; Ray K; Maji AK
    Asian Pac J Trop Med; 2013 Jun; 6(6):443-8. PubMed ID: 23711703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Artemisinin resistance in Myanmar--Authors' reply.
    Imwong M; Tun KM; Hlaing TM; Grist EP; Guerin P; Smithuis F; Dondorp AM; Day NP; Nosten F; White N; Woodrow CJ
    Lancet Infect Dis; 2015 Sep; 15(9):1002-1003. PubMed ID: 26333325
    [No Abstract]   [Full Text] [Related]  

  • 32. Artemisinin resistance needs to be defined rigorously to be understood: response to Dondorp and Ringwald.
    Krishna S; Kremsner PG
    Trends Parasitol; 2013 Aug; 29(8):361-2. PubMed ID: 23809865
    [No Abstract]   [Full Text] [Related]  

  • 33. Once-daily combination therapy for uncomplicated malaria: is this the way forward?
    Kokwaro G
    Clin Infect Dis; 2005 Aug; 41(4):433-4. PubMed ID: 16028148
    [No Abstract]   [Full Text] [Related]  

  • 34. Updates on k13 mutant alleles for artemisinin resistance in Plasmodium falciparum.
    Zaw MT; Emran NA; Lin Z
    J Microbiol Immunol Infect; 2018 Apr; 51(2):159-165. PubMed ID: 28711439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Possible artemisinin-based combination therapy-resistant malaria in Nigeria: a report of three cases.
    Ajayi NA; Ukwaja KN
    Rev Soc Bras Med Trop; 2013; 46(4):525-7. PubMed ID: 23982103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A call to action: addressing the challenge of artemisinin-resistant malaria.
    Kachur SP; MacArthur JR; Slutsker L
    Expert Rev Anti Infect Ther; 2010 Apr; 8(4):365-6. PubMed ID: 20377330
    [No Abstract]   [Full Text] [Related]  

  • 37. Emerging artemisinin resistance in the border areas of Thailand.
    Na-Bangchang K; Karbwang J
    Expert Rev Clin Pharmacol; 2013 May; 6(3):307-22. PubMed ID: 23656342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroauditory toxicity of artemisinin combination therapies-have safety concerns been addressed?
    Ramos-Martín V; González-Martínez C; Mackenzie I; Schmutzhard J; Pace C; Lalloo DG; Terlouw DJ
    Am J Trop Med Hyg; 2014 Jul; 91(1):62-73. PubMed ID: 24865683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Artemisinin resistance is a clear and present danger.
    Dondorp AM; Ringwald P
    Trends Parasitol; 2013 Aug; 29(8):359-60. PubMed ID: 23768981
    [No Abstract]   [Full Text] [Related]  

  • 40. Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: ethical and practical considerations.
    Tindana P; de Haan F; Amaratunga C; Dhorda M; van der Pluijm RW; Dondorp AM; Cheah PY
    Malar J; 2021 Feb; 20(1):119. PubMed ID: 33639946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.